Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Ruberg, Stephen J ^a   Chen, Lei ^b   Stauffer, Virginia ^a   Ascher Svanum, Haya ^b   Kollack Walker, Sara ^b   Conley, Robert R ^b   Kane, John ^c   Kinon, Bruce J ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly USA   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECISION TREE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SYMPTOM; TREATMENT RESPONSE; ADOLESCENT; COMPARATIVE STUDY; META ANALYSIS; MIDDLE AGED; PROBABILITY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DECISION TREES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROBABILITY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 79651470675     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-23     Document Type: Article

References (25)

1. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008, 102:230-240. 10.1016/j.schres.2008.02.021, 18423985.
2. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590. 10.1038/npp.2009.164, 19890258.
3. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 2008, 34:1163-1171. 10.1093/schbul/sbm134, 2632496, 18156640.
4. Kinon BJ, Ascher-Svanum H, Adams DH, Chen L. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials. J Clin Psychopharmacol 2008, 28:544-549. 10.1097/JCP.0b013e318185e74a, 18794651.
5. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008, 8:32. 10.1186/1471-244X-8-32, 2390550, 18447935.
6. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003, 60:1228-1235. 10.1001/archpsyc.60.12.1228, 14662555.
7. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005, 162:939-946. 10.1176/appi.ajp.162.5.939, 15863796.
8. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005, 57:1543-1549. 10.1016/j.biopsych.2005.02.023, 15953491.
9. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003, 160:2063-2065. 10.1176/appi.ajp.160.11.2063, 14594760.
10. Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007, 68:352-360. 10.4088/JCP.v68n0301, 17388703.
11. Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 2010,
12. Overall JE. The Brief Psychiatric Rating Scale. Psychological Measurements in Psychopharmacology, Modern Problems of Pharmacopsychiatry 1974, 7:67-78. Basel, Switzerland: S. Karger, Pichot P.
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
14. Breiman L, Freidman L, Olshen RA, Stone C. Classification and Regression Trees 1984, New York: Chapman & Hall (Wadsworth, Inc.).
15. Lemon SC, Roy J, Clark MA, Friedmann PD, Rakowski W. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med 2003, 26:172-181. 10.1207/S15324796ABM2603_02, 14644693.
16. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A, . HGGN Study Group One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006, 81:1-15. 10.1016/j.schres.2005.07.038, 16202565, HGGN Study Group.
17. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997, 17:407-418. 10.1097/00004714-199710000-00010, 9315992.
18. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005, 162:1879-1887. 10.1176/appi.ajp.162.10.1879, 16199834.
19. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006, 26:157-162. 10.1097/01.jcp.0000204137.82298.06, 16633144.
20. Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006, 26:453-461. 10.1097/01.jcp.0000236658.16286.25, 16974184.
21. Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008, 28:392-400. 10.1097/JCP.0b013e31817e63a5, 18626265.
22. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009, 70:572-581. 10.4088/JCP.08m04421, 19323965.
23. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised 1976, Rockville, MD: National Institute of Mental Health.
24. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984, 10:388-398.
25. Berry MJ, Gordon L. Data Mining Techniques for Marketing, Sales and Customer Relationship Management 2004, 166. Canada: John Wiley & Sons, Inc, 2.